$CRDF generated 9 mentions over a 12-month period from 2 distinct FinTwit voices, with the first mention appearing on July 29, 2025. @jacobplieth (@jacobplieth) dominated the conversation with 8 mentions, while @adamfeuerstein (@adamfeuerstein) contributed 1 mention. Discussion of Cardiff Oncology Inc centered on biotech developments, particularly surrounding clinical trial data for the company's onvansertib program.

Activity peaked on July 30, 2025, with multiple posts from @jacobplieth addressing phase 2 trial results. The most recent mentions on that date referenced baseline imbalances in trial data and associated stock movement, with @jacobplieth noting that $CRDF opened down 20% following the phase 2 data release and commenting on trial design specifications.